clinical trial · NCT04688164
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Major Depressive DisorderREL-1017Placebo
brief summary
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
started
Jan 8, 2021
primary completion
Nov 1, 2022
completion
Nov 10, 2022
last updated
Aug 27, 2024
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol